Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Florian Simon

Florian Simon

MD
University Hospital Cologne
Challenges & potential solutions for balancing efficacy and tolerability in older patients with CLL 1:24
Challenges & potential solutions for balancing efficacy and tolerability in older patients with CLL
Florian Simon • 7 Dec 2024
Efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with CLL 1:21
Efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with CLL
Florian Simon • 7 Dec 2024
How have novel agents changed the paradigm for treating older or frail patients with CLL? 1:35
How have novel agents changed the paradigm for treating older or frail patients with CLL?
Florian Simon • 7 Dec 2024
The use of surrogate endpoints in CLL clinical trials 3:32
The use of surrogate endpoints in CLL clinical trials
Florian Simon • 8 Oct 2023
Sequencing of therapies in patients with R/R CLL 2:34
Sequencing of therapies in patients with R/R CLL
Florian Simon • 8 Oct 2023
Associated toxicities of novel therapies for CLL 2:00
Associated toxicities of novel therapies for CLL
Florian Simon • 8 Oct 2023
The content of VJHemOnc is intended for healthcare professionals